Front Page VSPN Message Boards Chat Library Continual Education Search MyVSPN - Coming Soon Help Frequently Asked Questions Send us Feedback! Go to VIN Industry Partners Go to VetQuest Go to Veterinary Partner Go to Y2Spay
 
Menu bar   Go to the VIN.com Portal
 

ABSTRACT OF THE WEEK

Journal of feline medicine and surgery
Volume 13 | Issue 10 (October 2011)

Safety and palatability of polyethylene glycol 3350 as an oral laxative in cats.

J Feline Med Surg. October 2011;13(10):694-7.
Fiona M Tam1, Anthony P Carr, Sherry L Myers
1 Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada. fiona.tam@usask.ca
Crown Copyright © 2011. Published by Elsevier Ltd. All rights reserved.

Abstract

Recurrent constipation is a common problem in cats. Laxatives often are the cornerstone for management of recurrent constipation; however, there is a paucity of published research on laxative use in cats. This study investigated the safety and palatability of polyethylene glycol (PEG3350) in normal cats. All cats consumed the PEG3350 laxative for 4 weeks without changes in weight or food intake. In all cats soft stools were achieved. Effective doses varied widely in experimental cats, so individualized dosing is important. Mild, non-clinical hyperkalemia was noted although the cause is unknown.

Companion Notes

Report on the safety and palatability of polyethylene glycol 3350 as an oral laxative in normal cats

 

Study design

- introduction on the treatment of constipation in cats

- laxa­tives commonly used as part of management

- polyethylene glycol (PEG3350) is a bulking and softening agent

- large molecular weight, water-soluble polymer

- in human medicine widely used as an osmotic laxative

- not metabolized by intestinal bacterial

- minimally absorbed

- each molecule hydrogen bonds with 100 molecules of water

- this results in high osmotic pressures in bowel lumen

- this acts against the absorp­tion of water out of the lumen

- in multiple meta-analyses

- PEG3350 a more effec­tive laxative than lactulose

- as well as many other oral laxa­tives

- adverse events are self-limiting and include the following:

- distended abdomen with pain

- nausea

- ex­cessive diarrhea

- clinical hyponatremia not documented with daily low-dose use

- lactulose is a commonly used osmotic laxa­tive

- in human medicine

- moderate evidence of efficacy and safety for chronic constipation

- in veterinary medicine: no evidence to support use

- soluble and insoluble dietary fibers

- in human medicine

- weak evidence of efficacy and safety for chronic constipation

- in feline medicine: no evidence to support use

- study population: 6 healthy cats from 1-4 years of age in a closed colony

- there was no history of diarrhea or constipation in the colony

- procedure:

- pilot trial on 2 of the cats to deter­mine an effective initial dose

- treatment trial for 4 weeks

- PEG3350 with electrolytes (Colyte oral solution; Schwarz Pharma)

- 1.9 g per meal with the pow­der mixed with food

- cats were fed twice daily

(Iams, ProActive Adult formula, canned and dry)

- standard weight of canned and dry food offered each meal

- unconsumed amount weighed

- dosage titrated in each cat to achieve soft, formed stool (grade II-III)

- initial dose doubled if no effect seen within 48 hours

- assessment methods:

- fecal scores assessed daily; standardized fecal grading scale used

- grade I: over 66% of feces are liquid

- grade II: intermediate consistency between soft and liquid

- equal amounts of feces are soft and liquid

- grade III: over 66% of feces is soft

- firm enough to form a pile (no cylindrical appearance)

- grade IV: intermediate between firm and soft

- equal amounts of feces are firm and soft

- grade V: over 66% of feces in a defecation are firm

- cylindrical shape with little flattening

- CBC and chemistry before and 2 and 4 weeks after starting PEG3350

- palatability assessed by food intake and weight

- treatment stopped after 4 weeks

- cats monitored until stool consis­tency was normal for 2 defecations

 

Results

- grade I-III stool consistency achieved in all cats

- target consistency achieved in a median of 21.5 days

- median daily dose of powder to achieve target fecal grade: 3.0 ± 1.1 g

- median daily doses of the 6 cats to achieve target fecal grade

- 0.8, 1.5, 3.0, 3.0, 3.8 and 3.8 g

- dos­age may be highly variable between cats

- diarrhea occasionally noted during treatment, 4 cats

- PEG3350 dosage decreased

- median time to return to normal consistency after stopping: 5.5 ± 3.4 days

- adverse event: no significant side effects noted in any cat

- sporadic vomiting, 1 cat during the treatment

- mild hyperkalemia, 3 cats at 5.6-6.0 mmol/l with reference at 3.9-5.5 mmol/l

- not associated with clinical signs in any of the cats

- food intake and body weight not significantly changed by PEG3350

 

“Our study demonstrated that PEG3350 with electro­lytes is a safe and palatable oral laxative in healthy cats when used for 4 weeks. Potential side-effects in­clude hyperkalemia; however, the changes we noted were not clinically or statistically significant.”

 

 

Article Tools:

Archives Highlights:
Managing Compulsive Disorders in Cats
Treatment of compulsive disorder is aimed at reducing the frequency, intensity, and duration of compulsive episodes so that alternative behaviors can be trained and reinforced instead. Clients should be aware that treatment of these disorders will often require lifelong care to ensure that the cat maintains a good quality of life.
Xanthinuria secondary to allopurinol treatment in dogs with leishmaniosis: Current perspectives of the Iberian veterinary community.
Of two-hundred and thirty respondents, 99.6% prescribe allopurinol for canine leishmaniosis. Xanthinuria was estimated to happen in less than one out of every four dogs by 91.7% of the clinicians. Three out of every four respondents inform owners about deleterious effects of allopurinol, and 28.4% consider implementing a change in diet in advance of treatment as a proactive measure. When xanthinuria is detected, 43.2% of the respondents discontinue allopurinol, 24% replace it by nucleotide-analogs, 14.9% reduce its dosage, and 3.1% split its dosage but increase administration frequency.
Registered Medicinal Products for Use in Honey Bees in the United States and Canada.
The goal of this article is to summarize this information in an up-to-date, practical way for the clinician. At the time of this writing, only 3 antibiotics are approved for use in honey bees and require veterinary prescriptions or veterinary feed directives.
The Mitral INsufficiency Echocardiographic score: A severity classification of myxomatous mitral valve disease in dogs.
Median survival time was significantly different between the proposed severity classes: mild (2344?days, 95% confidence interval [CI] 1877-2810?days), moderate (1882?days, 95% CI 1341-2434?days), severe (623?days, 95% CI 432-710?days), and late stage (157?days, 95% CI 53-257?days). A MINE score >8 was predictive of cardiac death.
Validation of a flash glucose monitoring system in outpatient diabetic cats.
Paired interstitial glucose and automated biochemistry analyzer glucose concentrations (139 samples) had excellent correlation as did interstitial glucose and point-of-care glucometer glucose concentrations (142 samples). Sensor failure or displacement were recorded for 12/15 (80%) sensor placements. Median time of sensor activity was 7 days (range, 2-13 days).

Back Print Save Bookmark in my Browser Email this article to me. Top of Page. VSPN AOW : Safety and palatability o...
Contact Us